Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

Discover how tirzepatide benefits heart failure in obesity, and see why those with higher BMI may gain even more benefits.

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Check your insurance plan to be sure, but providers don’t often cover tirzepatide for weight loss. If they do, there might be some requirements you need to meet or copays and deductibles, so you ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, Chinese obese individuals can maintain significant ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

New study reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Here's what they found.